PURPOSE: Multiparametric magnetic resonance imaging (mpMRI) is used widely for prostate cancer (PCa) evaluation. Approximately 35% of aggressive tumors, however, are not visible on mpMRI. We sought to identify the molecular alterations associated with mpMRI-invisible tumors and determine whether mpMRI visibility is associated with PCa prognosis. METHODS: Discovery and validation cohorts included patients who underwent mpMRI before radical prostatectomy and were found to harbor both mpMRI-visible (Prostate Imaging and Reporting Data System 3 to 5) and -invisible (Prostate Imaging and Reporting Data System 1 or 2) foci on surgical pathology. Next-generation sequencing was performed to determine differential gene expression between mpMRI-visible and -invisible foci. A genetic signature for tumor mpMRI visibility was derived in the discovery cohort and assessed in an independent validation cohort. Its association with long-term oncologic outcomes was evaluated in a separate testing cohort. RESULTS: The discovery cohort included 10 patients with 26 distinct PCa foci on surgical pathology, of which 12 (46%) were visible and 14 (54%) were invisible on preoperative mpMRI. Next-generation sequencing detected prioritized genetic mutations in 14 (54%) tumor foci (n = 8 mpMRI visible, n = 6 mpMRI invisible). A nine-gene signature (composed largely of cell organization/structure genes) associated with mpMRI visibility was derived (area under the curve = 0.89), and the signature predicted MRI visibility with 75% sensitivity and 100% specificity (area under the curve = 0.88) in the validation cohort. In the testing cohort (n = 375, median follow-up 8 years) there was no significant difference in biochemical recurrence, distant metastasis, or cancer-specific mortality in patients with predicted mpMRI-visible versus -invisible tumors (all P > .05). CONCLUSION: Compared with mpMRI-invisible disease, mpMRI-visible tumors are associated with underexpression of cellular organization genes. mpMRI visibility does not seem to be predictive of long-term cancer outcomes, highlighting the need for biopsy strategies that detect mpMRI-invisible tumors.
PURPOSE: Multiparametric magnetic resonance imaging (mpMRI) is used widely for prostate cancer (PCa) evaluation. Approximately 35% of aggressive tumors, however, are not visible on mpMRI. We sought to identify the molecular alterations associated with mpMRI-invisible tumors and determine whether mpMRI visibility is associated with PCa prognosis. METHODS: Discovery and validation cohorts included patients who underwent mpMRI before radical prostatectomy and were found to harbor both mpMRI-visible (Prostate Imaging and Reporting Data System 3 to 5) and -invisible (Prostate Imaging and Reporting Data System 1 or 2) foci on surgical pathology. Next-generation sequencing was performed to determine differential gene expression between mpMRI-visible and -invisible foci. A genetic signature for tumor mpMRI visibility was derived in the discovery cohort and assessed in an independent validation cohort. Its association with long-term oncologic outcomes was evaluated in a separate testing cohort. RESULTS: The discovery cohort included 10 patients with 26 distinct PCa foci on surgical pathology, of which 12 (46%) were visible and 14 (54%) were invisible on preoperative mpMRI. Next-generation sequencing detected prioritized genetic mutations in 14 (54%) tumor foci (n = 8 mpMRI visible, n = 6 mpMRI invisible). A nine-gene signature (composed largely of cell organization/structure genes) associated with mpMRI visibility was derived (area under the curve = 0.89), and the signature predicted MRI visibility with 75% sensitivity and 100% specificity (area under the curve = 0.88) in the validation cohort. In the testing cohort (n = 375, median follow-up 8 years) there was no significant difference in biochemical recurrence, distant metastasis, or cancer-specific mortality in patients with predicted mpMRI-visible versus -invisible tumors (all P > .05). CONCLUSION: Compared with mpMRI-invisible disease, mpMRI-visible tumors are associated with underexpression of cellular organization genes. mpMRI visibility does not seem to be predictive of long-term cancer outcomes, highlighting the need for biopsy strategies that detect mpMRI-invisible tumors.
Authors: David C Johnson; Steven S Raman; Sohrab A Mirak; Lorna Kwan; Amirhossein M Bajgiran; William Hsu; Cleo K Maehara; Preeti Ahuja; Izak Faiena; Aydin Pooli; Amirali Salmasi; Anthony Sisk; Ely R Felker; David S K Lu; Robert E Reiter Journal: Eur Urol Date: 2018-12-01 Impact factor: 20.096
Authors: Hebert Alberto Vargas; Oguz Akin; Amita Shukla-Dave; Jingbo Zhang; Kristen L Zakian; Junting Zheng; Kent Kanao; Debra A Goldman; Chaya S Moskowitz; Victor E Reuter; James A Eastham; Peter T Scardino; Hedvig Hricak Journal: Radiology Date: 2012-09-05 Impact factor: 11.105
Authors: Jesse D Le; Nelly Tan; Eugene Shkolyar; David Y Lu; Lorna Kwan; Leonard S Marks; Jiaoti Huang; Daniel J A Margolis; Steven S Raman; Robert E Reiter Journal: Eur Urol Date: 2014-09-23 Impact factor: 20.096
Authors: Amirali Salmasi; Jonathan Said; Alan W Shindel; Pooria Khoshnoodi; Ely R Felker; Anthony E Sisk; Tristan Grogan; Debbie McCullough; John Bennett; Helen Bailey; H Jeffrey Lawrence; David A Elashoff; Leonard S Marks; Steven S Raman; Phillip G Febbo; Robert E Reiter Journal: J Urol Date: 2018-03-07 Impact factor: 7.450
Authors: Ashley E Ross; Michael H Johnson; Kasra Yousefi; Elai Davicioni; George J Netto; Luigi Marchionni; Helen L Fedor; Stephanie Glavaris; Voleak Choeurng; Christine Buerki; Nicholas Erho; Lucia L Lam; Elizabeth B Humphreys; Sheila Faraj; Stephania M Bezerra; Misop Han; Alan W Partin; Bruce J Trock; Edward M Schaeffer Journal: Eur Urol Date: 2015-06-06 Impact factor: 20.096
Authors: Ganesh S Palapattu; Simpa S Salami; Andi K Cani; Daniel H Hovelson; Lorena Lazo de la Vega; Kelly R Vandenberg; Jarred V Bratley; Chia-Jen Liu; Lakshmi P Kunju; Jeffery S Montgomery; Todd M Morgan; Shyam Natarajan; Jiaoti Huang; Scott A Tomlins; Leonard S Marks Journal: Clin Cancer Res Date: 2016-10-07 Impact factor: 12.531
Authors: Jan P Radtke; Timur H Kuru; Silvan Boxler; Celine D Alt; Ionel V Popeneciu; Clemens Huettenbrink; Tilman Klein; Sarah Steinemann; Claudia Bergstraesser; Matthias Roethke; Wilfried Roth; Heinz-Peter Schlemmer; Markus Hohenfellner; Boris A Hadaschik Journal: J Urol Date: 2014-07-28 Impact factor: 7.450
Authors: Daniel H Hovelson; Andrew S McDaniel; Andi K Cani; Bryan Johnson; Kate Rhodes; Paul D Williams; Santhoshi Bandla; Geoffrey Bien; Paul Choppa; Fiona Hyland; Rajesh Gottimukkala; Guoying Liu; Manimozhi Manivannan; Jeoffrey Schageman; Efren Ballesteros-Villagrana; Catherine S Grasso; Michael J Quist; Venkata Yadati; Anmol Amin; Javed Siddiqui; Bryan L Betz; Karen E Knudsen; Kathleen A Cooney; Felix Y Feng; Michael H Roh; Peter S Nelson; Chia-Jen Liu; David G Beer; Peter Wyngaard; Arul M Chinnaiyan; Seth Sadis; Daniel R Rhodes; Scott A Tomlins Journal: Neoplasia Date: 2015-04 Impact factor: 5.715
Authors: Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore Journal: N Engl J Med Date: 2018-03-18 Impact factor: 176.079
Authors: Alberto Artiles Medina; Rafael Rodríguez-Patrón Rodríguez; Mercedes Ruiz Hernández; Marina Mata Alcaraz; Silvia García Barreras; Guillermo Fernández Conejo; Agustín Fraile Poblador; Enrique Sanz Mayayo; Francisco Javier Burgos Revilla Journal: Res Rep Urol Date: 2021-09-27
Authors: Amanda Khoo; Lydia Y Liu; Taylor Y Sadun; Amirali Salmasi; Aydin Pooli; Ely Felker; Kathleen E Houlahan; Vladimir Ignatchenko; Steven S Raman; Anthony E Sisk; Robert E Reiter; Paul C Boutros; Thomas Kislinger Journal: J Hematol Oncol Date: 2022-05-03 Impact factor: 23.168
Authors: Yi Zhao; Benjamin S Simpson; Naomi Morka; Alex Freeman; Alex Kirkham; Daniel Kelly; Hayley C Whitaker; Mark Emberton; Joseph M Norris Journal: Cancers (Basel) Date: 2022-07-19 Impact factor: 6.575
Authors: Jeffrey J Tosoian; Bruce J Trock; Todd M Morgan; Simpa S Salami; Scott A Tomlins; Daniel E Spratt; Javed Siddiqui; Lakshmi P Kunju; Rachel Botbyl; Zoey Chopra; Balaji Pandian; Nicholas W Eyrich; Gary Longton; Yingye Zheng; Ganesh S Palapattu; John T Wei; Yashar S Niknafs; Arul M Chinnaiyan Journal: J Urol Date: 2020-10-20 Impact factor: 7.450
Authors: Joseph M Norris; Benjamin S Simpson; Marina A Parry; Clare Allen; Rhys Ball; Alex Freeman; Daniel Kelly; Hyung L Kim; Alex Kirkham; Sungyong You; Veeru Kasivisvanathan; Hayley C Whitaker; Mark Emberton Journal: Eur Urol Open Sci Date: 2020-07